EndoStim postpones IPO; Sorin expands in Germany;

@FierceMedDev: New microscope offers 3D cellular images that are fast, detailed and low toxicity. More | Follow @FierceMedDev

@VarunSaxena2: Bard Q3 earnings up 41% as it focuses on Lutonix launch. Story | Follow @VarunSaxena2

@EmilyWFierce: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

> San Francisco-based Sympara Medical raised $5.5 million in funding to use towards the development of a device to treat hypertension. More

> EndoStim, a company selling neurostimulation devices used to treat gastroesophageal reflux disease, postponed its IPO on Thursday citing poor market conditions. More

> Zyno Medical received 510(k) clearance for its Nimbus Ambulatory Infusion Pump designed to deliver medications and fluids to a patient needing subcutaneous, epidural, perineural or intravenous infusions. Release

> Cardiovascular medical device company Sorin Group expanded its Munich, Germany manufacturing facility to develop more cardiopulmonary technology. Release

Biotech News

@FierceBiotech: $GSK cozies up to Five Prime for respiratory R&D. More | Follow @FierceBiotech

@JohnCFierce: Baxter gets FDA OK for hemophilia A drug -- Obizur. News | Follow @JohnCFierce

@DamianFierce: $AZN's olaparib will trade as Lynparza, which sounds like a nice lady. | Follow @DamianFierce

@EmilyMFierce: Researchers will test blood of Ebola survivors to use as a short-term treatment option. Story | Follow @EmilyMFierce

> AstraZeneca gets some EU encouragement for its $2B cancer hopeful. More

> Shire CFO to exit in wake of failed AbbVie deal. Chutes & Ladders

> NPS Pharma will have to wait another three months for an FDA OK. News

Pharma News

@FiercePharma: Top-read in FiercePharma Thurs: Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it weekly, subscribe. Subscribe | Follow @CarlyHFierce

> Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings. Story

> What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid? More

> Actavis primed for another deal, or two, or maybe three. Article

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.